Skip to Content
Merck
  • Effects of oral hyposensitization therapy with nickel on haemoglobin and haematocrit values in sensitized patients.

Effects of oral hyposensitization therapy with nickel on haemoglobin and haematocrit values in sensitized patients.

International journal of immunopathology and pharmacology (2012-06-16)
A Tammaro, A Narcisi, P P Di Russo, C Abruzzese, C Caperchi, F Persechino, F R Parisella, S Persechino
ABSTRACT

Nickel deficiency leads to reduced iron content in organs and to reduced hemoglobin levels and haematocrit counts. We carried out a clinical trial of oral hyposensitization therapy with low doses of nickel on a group of 20 patients affected by systemic allergy to this sensitizer element and with a chronic relapsing low hemoglobin level and haematocrit count. We obtained interesting results on maintaining these values in treated patients.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Nickel(II) sulfate, anhydrous, 99.99% trace metals basis
Sigma-Aldrich
Nickel(II) sulfate hexahydrate, ACS reagent, ≥98%
Sigma-Aldrich
Nickel(II) sulfate hexahydrate, ReagentPlus®, powder or crystals
Supelco
Nickel(II) sulfate hexahydrate, ≥99.99% trace metals basis
Sigma-Aldrich
Nickel(II) sulfate heptahydrate, 99.999% trace metals basis
Sigma-Aldrich
Nickel(II) sulfate hexa-/ heptahydrate, for nickel plating, DIN 50970 H, ≥20.6% Ni and Co basis
Sigma-Aldrich
Nickel(II) sulfate heptahydrate, purum p.a., crystallized, ≥99.0% (KT)